Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast Cancer.

ABSTRACT:

SUBMITTER: Bowles HJ 

PROVIDER: S-EPMC5017548 | biostudies-literature | 2015 Nov-Dec

REPOSITORIES: biostudies-literature